View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 28, 2018

Deals this week: Mylan, Daiichi Sankyo, Takeda

Mylan has formed a partnership with Atomo Diagnostics to expand access to HIV self-testing products in developing and under-developed countries.

Mylan has formed a partnership with Atomo Diagnostics to expand access to HIV self-testing products in developing and under-developed countries.

Mylan has gained exclusive rights to commercialise Atomo Diagnostics’ in-vitro HIV rapid diagnostic test products in more than 100 countries in Africa, Asia, the Middle East, and Latin America through the agreement.

Based in the US, Mylan is a pharmaceutical company engaged in the development of over-the-counter (OTC) drugs, while Atomo Diagnostics is a medical device company engaged in the development of in-vitro diagnostic products.

The partnership will enable the two companies to provide all-in-one test devices, designed to improve functionality and ease-of-use when compared to current multi-component diagnostic tests.

Daiichi Sankyo has signed a clinical research collaboration agreement with Merck’s subsidiary to evaluate its investigational HER2 targeting antibody drug conjugate DS-8201 and Keytruda® (pembrolizumab) in HER2 expressing advanced/metastatic breast and HER2 mutant non-small cell lung cancers.

DS-8201 is designed to target and deliver chemotherapy inside cancer cells, while Keytruda® is the first anti-PD-1 (programmed death receptor-1) therapy indicated for the treatment of unresectable or metastatic melanoma.

“Takeda Pharmaceutical has signed a commercialisation agreement with Molecular Templates to develop protein-based oncology therapies for cancer treatment.”

Daiichi Sankyo will conduct a two-part, multi-centre, open-label study to evaluate the safety and efficacy of DS-8201 and Keytruda® in cancer patients across the US and Europe.

Based in Japan, Daiichi Sankyo is a pharmaceutical company engaged in the development of therapies in the areas of hypertension and diabetes, while Merck is a healthcare solutions provider based in the US.

Takeda Pharmaceutical has signed a commercialisation agreement with Molecular Templates to develop protein-based oncology therapies for cancer treatment.

The two companies will focus on the development of CD38-targeted engineered toxin bodies (ETBs) for the treatment of patients suffering from multiple myeloma.

Molecular Templates will receive an upfront payment of $30m from Takeda and up to $632.5m in milestone payments upon exercising its co-development option, as per the the agreement.

Based in Japan, Takeda is engaged in the development of pharmaceuticals for metabolic and cardiovascular diseases, while Molecular Templates is a US-based clinical-stage biopharmaceutical company engaged in the development of therapeutics for cancer.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology